Head-to-head evidence
Mezigdomide vs Thalidomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Mezigdomide
Developed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT05372354 (registry estimate)
Thalidomide
Marketed by Bristol-Myers Squibb
NCT00083551 · Phase 3 · completed
The trial randomly assigned 323 participants to thalidomide and 345 to no thalidomide, but treatment was open-label rather than blinded. Its primary endpoint was the hard clinical outcome of six-year overall survival; although the reported percentages favored thalidomide, statistical significance cannot be determined from the posted registry data.
Next expected readout: August 2027 · NCT00572169 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mezigdomide's landscape · Thalidomide's landscape